Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Oct 13, 2022 | Press Releases

CUPERTINO, CA / October 13, 2022 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor Conference

Sep 26, 2022 | Press Releases

CUPERTINO, Calif., Sept. 26, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 7, 2022 | Press Releases

CUPERTINO, Calif., Sept. 07, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Sep 6, 2022 | Press Releases

CUPERTINO, Calif., Sept. 06, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Aug 15, 2022 | Press Releases

– Enrollment on pace for ongoing pivotal Phase 3 RECOVER trial – – Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in mid-2023 – – $19.4 Million in Cash as of June 30, 2022 – CUPERTINO, Calif., Aug. 15,...